AC Immune SA

From Verify.Wiki
Jump to: navigation, search
AC Immune SA
Type Public
Industry Biotechnology
Founded 2003
Headquarters Lausanne, Switzerland
Key people Andrea Pfeifer (Co-Founder & CEO), Jean-Fabien Monin (CFO), Andreas Muhs (CSO) [1]
Investors Dietmar Hopp
Number of employees 62 [2]

AC Immune SA, a clinical stage Swiss-based biopharmaceutical company, focuses on neurodegenerative diseases with three product candidates in clinical trials. It designs, discovers, and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. The company’s technology platforms create antibodies, small molecules, and vaccines to address a broad spectrum of neurodegenerative indications. It offers its therapies to address Alzheimer disease and neurodegenerative diseases, such as Parkinson’s, Down syndrome, and glaucoma.
AC Immune SA was founded in 2003 and is based in Lausanne, Switzerland. [3]



Top 5 Recent Tweets

September 26, 2022newsfilterioForm 6-K (report of foreign issuer [rules 13a-16 and 15d-16]) filed with the SEC $ACIU
September 26, 2022stigmabaseFighting Stigma — AC Immune SA (ACIU) Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage ...: ... and we…
September 26, 2022quantisnow$ACIU 📜 SEC Form 6-K filed by AC Immune SA

45 seconds delayed.
September 22, 2022MaiiMerenda$ACIU Trading Signals | (NASDAQ) Stock Rating Changed to Hold: Ac Immune Sa. >>
September 20, 2022fundamentalsbotAC Immune SA's quarterly revenue growth rate YoY of -11.10% ranked 3495 out of 5749 companies in our database.…

Top 5 Recent News Headlines

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines


Verification history